Two New Tools for VMS: A Clinical and Pharmacological Comparison of NK Receptor Antagonists

In this episode, 'Two New Tools for VMS: A Clinical and Pharmacological Comparison of NK Receptor Antagonists,' the panelists explore the following questions:

1. What are the latest developments to the non-hormonal treatment landscape for VMS? What are key similarities and differences between their mechanism of action and prescribing information?
2. How do the half-life data compare between elinzanetant and fezolinetant, and are these differences clinically meaningful?

The panelists examined the key mechanistic distinction between fezolinetant and elinzanetant, noting that while fezolinetant selectively targets the NK3 receptor, elinzanetant is a dual NK1 and NK3 receptor antagonist, a difference that has meaningful clinical implications, particularly for patients whose VMS is accompanied by significant sleep disturbance, given the emerging evidence linking NK1 receptor activity to sleep regulation. The discussion also explored important pharmacological differences between the two agents, including their distinct cytochrome metabolic pathways, their markedly different half-lives, and the practical implications of these differences for drug interactions, side effect duration, and dosing. The panelists further highlighted key clinical considerations to guide treatment selection and patient counseling, including the more intensive liver function monitoring required for fezolinetant, the transient but potentially significant daytime somnolence associated with elinzanetant initiation, and the practical challenge of elinzanetant's large capsule size, particularly for older patients or those with swallowing difficulties.

Throughout the conversation, the experts provide a comprehensive reflection on the field and the factors that may shape how clinicians approach care moving forward.

The next episode in this series, 'From Trial to Practice: Key Findings from the SKYLIGHT and OASIS Studies,' features the panelists advancing their conversation on vasomotor symptoms and menopause and focusing on the primary and secondary endpoints of the SKYLIGHT and OASIS clinical trials, how quickly patients experienced symptom improvement in each study, and what the trial data revealed about sleep disturbance outcomes for both fezolinetant and elinzanetant.